^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SAAL1 overexpression

    i
    Other names: SAAL1, Serum Amyloid A Like 1, Synoviocyte Proliferation-Associated In Collagen-Induced Arthritis Protein 1, Protein SAAL1, FLJ41463, SPACIA1, Synoviocyte Proliferation-Associated In Collagen-Induced Arthritis 1
    Entrez ID:
    113174
    over1year
    Comprehensive analysis of the oncogenic potential of eukaryotic initiation factor 3M via SAAL1 interaction in lung adenocarcinoma. (PubMed, Am J Cancer Res)
    The EIF3M/SAAL1 promote oncogenic cellular programs and immunosuppressive microenvironments that conferred unfavorable prognosis. These findings nominate EIF3M/SAAL1 as potential therapeutic targets and biomarkers in LUAD.
    Journal
    |
    SAA1 (Serum Amyloid A1) • SAAL1 (Serum Amyloid A Like 1)
    |
    SAA1 overexpression • SAAL1 overexpression
    almost3years
    The effects of the prognostic biomarker SAAL1 on cancer growth and its association with the immune microenvironment in lung adenocarcinoma. (PubMed, BMC Cancer)
    Inhibition of SAAL1 expression could regulate cancer growth via cyclin D1 and Bcl-2. SAAL1 is a promising prognostic biomarker in LAC patients.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • CCND1 (Cyclin D1) • SAA1 (Serum Amyloid A1) • SAAL1 (Serum Amyloid A Like 1)
    |
    BCL2 expression • CCND1 expression • SAA1 overexpression • SAAL1 overexpression
    over3years
    SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer. (PubMed, Aging (Albany NY))
    Lastly, we showed that SAAL1 silencing suppresses both malignant phenotype and expression of PD-L1 in lung cancer A549 cells in vitro. These findings suggest that SAAL1 contributes to tumorigenesis and antitumor immunity mechanisms in different cancer types, and may thus serve as both a prognostic biomarker and potential target for cancer immunotherapy.
    Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule) • SAA1 (Serum Amyloid A1) • SAAL1 (Serum Amyloid A Like 1)
    |
    PD-L1 expression • SAA1 overexpression • SAAL1 overexpression